Pharmacy Search
Vertice Login
Menu
close

Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.
← Back to Medmonitor

Medication Type: Alzheimer’s

Namzaric® (memantine and donepezil hydrochloride) extended release capsules

Approval Date: Dec 2023

Note: First-Time Generic

Indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily

Leqembi™ (lecnemab-irmb) injection

Approval Date: Jan 2023

Note: New Product

Indicated for the treatment of Alzheimer’s in patients with mild cognitive impairment or mild dementia sage of the disease

Adlarity (donepezil hydrochloride) transdermal system

Approval Date: Mar 2022

Note: New Product

Indicated for the treatment of mild-to-severe dementia of the Alzheimer’s type. This product is the first transdermal patch for this indication.

ADUHELM™ (ADUCANUMAB-AVWA) INJECTION

Approval Date: Jun 2021

Note: New Product

A first-of-its-kind, biologic treatment for Alzheimer’s disease. This drug is the first new Alzheimer’s drug since 2003

Medication Name

Approval Date

Category

Description

Namzaric® (memantine and donepezil hydrochloride) extended release capsules

Dec 2023

Indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily

Note: First-Time Generic

Leqembi™ (lecnemab-irmb) injection

Jan 2023

Indicated for the treatment of Alzheimer’s in patients with mild cognitive impairment or mild dementia sage of the disease

Note: New Product

Adlarity (donepezil hydrochloride) transdermal system

Mar 2022

Indicated for the treatment of mild-to-severe dementia of the Alzheimer’s type. This product is the first transdermal patch for this indication.

Note: New Product

ADUHELM™ (ADUCANUMAB-AVWA) INJECTION

Jun 2021

A first-of-its-kind, biologic treatment for Alzheimer’s disease. This drug is the first new Alzheimer’s drug since 2003

Note: New Product
lockenvelopephone-handsetmagnifiermenucross-circle